UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): ~~January~~February 198, 2023

BIONIK LABORATORIES CORP.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		000-54717		27-1340346
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(IRS Employer Identification No.)

80 Coolidge Hill Road

Watertown, MA

02472

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 926-4800

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Not applicable		Not applicable		Not applicable

Item 52.~~07 Submission~~02 Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition

~~The~~On ~~Annual~~February ~~Meeting~~8, of2023, ~~Stockholders (the “Annual Meeting”) of~~ Bionik Laboratories Corp. ~~(the “Company”) was held on January 19, 2023. At the Annual Meeting, the stockholders~~ ofissued ~~the~~a ~~Company~~press ~~voted~~release onannouncing ~~the~~its ~~following~~financial ~~two~~results ~~proposals~~ and ~~cast~~corporate ~~their~~highlights ~~votes~~for ~~as described below. The proposals are described in more detail in~~ the ~~Company’s~~fiscal ~~Definitive~~quarter ~~Proxy~~ended ~~Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on~~ December 731, 2022.

~~Proposal~~A ~~1: Election~~copy of the ~~seven~~press ~~nominees listed~~release ~~below~~is furnished as Exhibit 99.1 to ~~serve~~this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for the ~~Board~~purposes of ~~Directors~~Section 18 of the ~~Company~~Securities Exchange ~~until~~Act ~~the~~of ~~next~~1934, ~~Annual~~as ~~Meeting~~amended, or otherwise subject to the liabilities of ~~Stockholders~~that ~~and~~section. ~~until~~This ~~their~~report ~~respective~~will not be deemed an admission ~~successors~~as ~~have~~to ~~been~~the ~~duly~~materiality ~~elected~~of ~~and~~any ~~qualified:~~information herein (including Exhibit 99.1).

Nominee	For	Withhold Authority	Broker Non-votes
Andre Auberton-Herve	3,489,934	7,803	75,827
Remi Gaston-Dreyfus	3,490,768	6,969	75,827
Rich Russo Jr.	3,493,270	4,467	75,827
Joseph Martin	3,490,768	6,969	75,827
Charles Matine	3,490,768	6,969	75,827
Audrey Thevenon	3,490,768	6,969	75,827
Michal Prywata	3,490,768	6,969	75,827

Proposal 2: To ratify MNP, LLP as the Company’s independent public accountants for the year ending March 31, 2023.

For	Against	Abstain
3,566,547	5,337	1,680

Item 9.01

Financial Statements and Exhibits.

Exhibit		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: ~~January~~February 208, 2023

BIONIK LABORATORIES CORP. By: /s/ ~~Rich~~Dan ~~Russo~~Gonsalves ~~Jr.~~ Name: ~~Rich~~Dan ~~Russo~~Gonsalves ~~Jr.~~ Title: Executive Vice President and Chief ~~Executive~~Financial Officer

Filing Compare · Bionik Laboratories Corp.